Resmed Inc (RMD) SEC Filing 10-K Annual report for the fiscal year ending Monday, June 30, 2014

Exhibit 99.1

RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014

Fourth quarter revenue of $415 million

Fourth quarter GAAP earnings per share of $0.61 and non-GAAP earnings per share of $0.64

Operating cash flow of $115.6 million in the fourth quarter

Quarterly dividend increased by 12% to $0.28 per share

SAN DIEGO, July 31, 2014

The results for the quarter ended June 30, 2014 were impacted by a $6.3 million ($4.2 million, net of tax) expense for restructuring charges relating to employee termination benefits associated with our reorganization of our commercial and research and development teams. Non-GAAP net income for the quarter ended June 30, 2014 was $92.0 million, a 1 percent increase compared to the quarter ended June 30, 2013 (non-GAAP measures exclude the impact of the restructuring expenses in the current quarter and the charge for Sydney University education, research and settlement expenses in the prior year quarter). Non-GAAP diluted earnings per share for the quarter were $0.64, a 3 percent increase compared to the quarter ended June 30, 2013.

“Our fourth quarter results were lower than anticipated, the result of softer sales in the Americas, partially offset by good growth in our international markets,” said ResMed Chief Executive Officer Mick Farrell. “We continue to benefit from our globally diversified business, with constant currency revenue growth of 5 percent in our combined Europe and Asia-Pacific businesses.”

Highlighting ResMed’s new products, Farrell continued, “We see good adoption of our AirFit™ P10 nasal pillows system which is currently the market leader among new patients, and although it is early, we are seeing encouraging traction for our AirFit™ N10 nasal mask and AirFit™ F10 full-face mask which were launched in the fourth quarter around the world. On the flow generator side in the fourth quarter, we launched the Astral™ platform, our new generation of life support ventilators, and are seeing strong uptake in Europe and Asia as sales begin to ramp. During the fourth quarter, we received FDA clearance for the Astral platform in the U.S. and anticipate a U.S. launch by the end of the calendar year.”